Dissecting Ph-like ALL: The Role of Genomic Lesion and Minimal Residual Disease in Refining Outcome

Cardinali, Deborah; Starza, Irene Della; Bellomarino, Vittorio; Beldinanzi, Marco; Trani, Mariangela Di; Ferrara, Felicetto; Bocchia, Monica; Salutari, Prassede; Lunghi, Monia; Borlenghi, Erika; Piccini, Matteo; Califano, Catello; Piciocchi, Alfonso; Propris, Maria Stefania De; Foà, Robin; Chiaretti, Sabina

doi:10.1182/blood-2022-163559

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In Ph-like ALL, there has been an observed tendency for early relapse after blinatumomab treatment despite becoming MRD-negative. This was evidenced by a sub-analysis on a cohort of Ph-like ALL cases enrolled in the GIMEMA LAL2317 protocol and may call for a more targeted follow-up approach in these patients ( 39 ).…”

Section: The Current and Future State Of Blinatumomab In Frontline Re...mentioning

confidence: 99%

Positioning blinatumomab in the frontline of adult B-cell acute lymphoblastic leukemia treatment

Pourhassan,

Agrawal,

Pullarkat

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

Blinatumomab is a bispecific T cell engager that has shown efficacy in relapsed/refractory Philadelphia chromosome (Ph)-positive and Ph-negative acute lymphoblastic leukemia (ALL). Considering its favorable safety and activity in advanced ALL, blinatumomab as a targeted immunotherapy is fast gaining a frontline position in the ALL treatment paradigm. There have been multiple completed and ongoing studies showing significant promise with improved response rates and survival outcomes and decreased treatment toxicity and need for multi-agent chemotherapy regimens. The early use of blinatumomab has established success in Ph-negative and Ph-positive B-ALL, and this has extended to older adults with ALL who have historically had substantially inferior outcomes compared to their pediatric and young adult counterparts. Herein we will review the current data describing the early use of blinatumomab in newly diagnosed adults with B-cell ALL and future directions.

show abstract

Section: The Current and Future State Of Blinatumomab In Frontline Re...mentioning

confidence: 99%

Positioning blinatumomab in the frontline of adult B-cell acute lymphoblastic leukemia treatment

Pourhassan,

Agrawal,

Pullarkat

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Recently, a predictive and statistical model based on Q-RT-PCR has evolved for the identification of Ph-like ALL cases [ 51 , 52 ]. A stepwise simple diagnostic algorithm adopted from Yadav V et al summarized the current Ph-like ALL genetic testing, illustrated in (Fig.…”

Section: Diagnostic Approaches To Ph-like Allmentioning

confidence: 99%

Philadelphia-like acute lymphoblastic leukemia: the journey from molecular background to the role of bone marrow transplant—review article

2023

View full text Add to dashboard Cite

Philadelphia chromosome-like (Ph-like) ALL is a recent subtype of acute lymphoblastic leukemia. Although it does not express the BCR-ABL fusion gene, it has a behavior like true BCR/ABL1–positive cases. This subtype harbors different molecular alterations most commonly CRLF2 rearrangements. Most cases of Ph-like ALL are associated with high white blood cell count, high minimal residual disease level after induction therapy, and high relapse rate. Efforts should be encouraged for early recognition of Ph-like ALL to enhance therapeutic strategies. Recently, many trials are investigating the possibility of adding the tyrosine kinase inhibitor (TKI) to chemotherapy to improve clinical outcomes. The role and best timing of allogeneic bone marrow transplant in those cases are still unclear. Precision medicine should be implemented in the treatment of such cases. Here in this review, we summarize the available data on Ph-like ALL

show abstract

Predicting relapse in acute lymphoblastic leukemia

Schwartz,

Muffly

2024

Leukemia & Lymphoma

View full text Add to dashboard Cite

Dissecting Ph-like ALL: The Role of Genomic Lesion and Minimal Residual Disease in Refining Outcome

Cited by 3 publications

References 0 publications

Positioning blinatumomab in the frontline of adult B-cell acute lymphoblastic leukemia treatment

Positioning blinatumomab in the frontline of adult B-cell acute lymphoblastic leukemia treatment

Philadelphia-like acute lymphoblastic leukemia: the journey from molecular background to the role of bone marrow transplant—review article

Predicting relapse in acute lymphoblastic leukemia

Contact Info

Product

Resources

About